Co-Diagnostics, Inc. (CODX) Form 8-K — Aug 13, 2026
Co-Diagnostics reported Q2 2026 revenue of $0.17 million, up slightly from $0.16 million a year ago, with a net loss of $6.3 million ($1.46 per basic and diluted share) versus a $7.7 million loss ($7.00 per share) in Q2 2025. Operating expenses fell to $6.3 million from $8.2 million, and adjusted EBITDA loss narrowed to $5.8 million from $7.2 million. On the regulatory front, the company submitted an FDA 510(k) premarket notification with a concurrent CLIA Waiver by Application for its Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument, supported by a clinical study of more than 1,400 patients across nine U.S. sites and 27 analytical studies spanning over 10,000 PCR test runs.
Key figures
- Revenue
- 166131
- Revenue Yoy
- +2.0% (derived from stated $162,910 in Q2 2025)
- Total Assets
- 16590631
- Cash Position
- 3649632
- Shares Outstanding
- 4878957
- Pcr test runs
- 10,000+
- Q2 2025 revenue
- 162910
- Cash dec 31 2025
- 11884607
- Us clinical sites
- 9
- Analytical studies
- 27
- Vector smart states
- 21
- Clinical study patients
- 1,400+
- Operating expenses q2 2025
- 8188568
- Operating expenses q2 2026
- 6321611
- New vector installations q2
- 4
- Private placement raise usd
- 3000000
- Shares outstanding dec 31 2025
- 2095031
- Weighted avg shares basic diluted
- 4309997
Price after filing
Close on the filing date to close N calendar days later (from $1.49). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.